Background: An international workshop on cancer predisposition cascade genetic screening for hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) took place in Switzerland, with leading researchers and clinicians in cascade screening and hereditary cancer from different disciplines. The purpose of the workshop was to enhance the implementation of cascade genetic screening in Switzerland. Participants discussed the challenges and opportunities associated with cascade screening for HBOC and LS in Switzerland (CASCADE study); family implications and the need for family-based interventions; the need to evaluate the cost-effectiveness of cascade genetic screening; and interprofessional collaboration needed to lead this initiative. Methods: The workshop aims were achieved through exchange of data and experiences from successful cascade screening programs in the Netherlands, Australia, and the state of Ohio, USA; Swiss-based studies and scientific experience that support cancer cascade screening in Switzerland; programs of research in psychosocial oncology and family-based studies; data from previous cost-effectiveness analyses of cascade genetic screening in the Netherlands and in Australia; and organizational experience from a large interprofessional collaborative. Scientific presentations were recorded and discussions were synthesized to present the workshop findings. Results: The key elements of successful implementation of cascade genetic screening are a supportive network of stakeholders and connection to complementary initiatives; sample size and recruitment of relatives; centralized organization of services; data-based cost-effectiveness analyses; transparent organization of the initiative; and continuous funding. Conclusions: This paper describes the processes and key findings of an international workshop on cancer predisposition cascade screening, which will guide the CASCADE study in Switzerland.

1.
National Academies of Sciences, Engineering, and Medicine.
2018
. Implementing and evaluating genomic screening programs in health care systems: Proceedings of a workshop. Washington, DC: The National Academies Press (doi: ) .
2.
Khoury
MJ
,
Gwinn
M
,
Bowen
MS
,
Dotson
WD
.
Beyond base pairs to bedside: a population perspective on how genomics can improve health
.
Am J Public Health
.
2012
Jan
;
102
(
1
):
34
7
.
[PubMed]
0090-0036
3.
Roberts
MC
,
Dotson
WD
,
DeVore
CS
,
Bednar
EM
,
Bowen
DJ
,
Ganiats
TG
, et al
Delivery Of Cascade Screening For Hereditary Conditions: A Scoping Review Of The Literature
.
Health Aff (Millwood)
.
2018
May
;
37
(
5
):
801
8
.
[PubMed]
0278-2715
4.
Snowsill
T
,
Huxley
N
,
Hoyle
M
,
Jones-Hughes
T
,
Coelho
H
,
Cooper
C
, et al
A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome
.
Health Technol Assess
.
2014
Sep
;
18
(
58
):
1
406
.
[PubMed]
1366-5278
5.
Centers for Disease Control and Prevention
, Office of Public Health Genomics: Evaluating Genomic Tests. [Retrieved from: https://www.cdc.gov/genomics/gtesting/index.htm ; accessed 05.09.2018].
6.
Khoury
MJ
,
Evans
JP
.
A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit
.
JAMA
.
2015
Jun
;
313
(
21
):
2117
8
.
[PubMed]
0098-7484
7.
Khoury
MJ
,
Gwinn
M
,
Dotson
WD
,
Schully
SD
.
Knowledge integration at the center of genomic medicine
.
Genet Med
.
2012
Jul
;
14
(
7
):
643
7
.
[PubMed]
1098-3600
8.
Grosse
SD
,
Rogowski
WH
,
Ross
LF
,
Cornel
MC
,
Dondorp
WJ
,
Khoury
MJ
.
Population screening for genetic disorders in the 21st century: evidence, economics, and ethics
.
Public Health Genomics
.
2010
;
13
(
2
):
106
15
.
[PubMed]
1662-4246
9.
Giardiello
FM
,
Allen
JI
,
Axilbund
JE
,
Boland
CR
,
Burke
CA
,
Burt
RW
, et al
Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer
.
Am J Gastroenterol
.
2014
Aug
;
109
(
8
):
1159
79
.
[PubMed]
0002-9270
10.
Kalady
MF
,
Heald
B
.
Diagnostic Approach to Hereditary Colorectal Cancer Syndromes
.
Clin Colon Rectal Surg
.
2015
Dec
;
28
(
4
):
205
14
.
[PubMed]
1531-0043
11.
Gupta
S
,
Provenzale
D
,
Regenbogen
SE
,
Hampel
H
,
Slavin
TP
 Jr
,
Hall
MJ
, et al
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017
.
J Natl Compr Canc Netw
.
2017
Dec
;
15
(
12
):
1465
75
.
[PubMed]
1540-1405
12.
Syngal
S
,
Brand
RE
,
Church
JM
,
Giardiello
FM
,
Hampel
HL
,
Burt
RW
;
American College of Gastroenterology
.
ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes
.
Am J Gastroenterol
.
2015
Feb
;
110
(
2
):
223
62
.
[PubMed]
0002-9270
13.
Vasen
HF
,
Blanco
I
,
Aktan-Collan
K
,
Gopie
JP
,
Alonso
A
,
Aretz
S
, et al;
Mallorca group
.
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts
.
Gut
.
2013
Jun
;
62
(
6
):
812
23
.
[PubMed]
0017-5749
14.
National Comprehensive Cancer Network (NCCN)
. Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Fort Washington, PA: NCCN; 2018. Ver. 1.
2018
. [Current version available online at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (free registration required); accessed 11 July 2018].
15.
National Comprehensive Cancer Network (NCCN)
. Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal. Fort Washington, PA: NCCN; 2017. Ver. 3.
2017
. [Current version available online at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (free registration required); accessed 11 July 2018].
16.
Katapodi
MC
,
Viassolo
V
,
Caiata-Zufferey
M
,
Nikolaidis
C
,
Bührer-Landolt
R
,
Buerki
N
, et al
Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: study Protocol
.
JMIR Res Protoc
.
2017
Sep
;
6
(
9
):
e184
.
[PubMed]
1929-0748
17.
Umans-Eckenhausen
MA
,
Defesche
JC
,
Sijbrands
EJ
,
Scheerder
RL
,
Kastelein
JJ
.
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
.
Lancet
.
2001
Jan
;
357
(
9251
):
165
8
.
[PubMed]
0140-6736
18.
Besseling
J
,
Sjouke
B
,
Kastelein
JJ
.
Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)
.
Atherosclerosis
.
2015
Aug
;
241
(
2
):
597
606
.
[PubMed]
0021-9150
19.
Broekhuizen
K
,
van Poppel
MN
,
Koppes
LL
,
Kindt
I
,
Brug
J
,
van Mechelen
W
.
Can multiple lifestyle behaviours be improved in people with familial hypercholesterolemia? Results of a parallel randomised controlled trial
.
PLoS One
.
2012
;
7
(
12
):
e50032
.
[PubMed]
1932-6203
20.
Jansen
AC
,
van Aalst-Cohen
ES
,
Tanck
MW
,
Trip
MD
,
Lansberg
PJ
,
Liem
AH
, et al
The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients
.
J Intern Med
.
2004
Dec
;
256
(
6
):
482
90
.
[PubMed]
0954-6820
21.
Kramer
A
,
Jansen
AC
,
van Aalst-Cohen
ES
,
Tanck
MW
,
Kastelein
JJ
,
Zwinderman
AH
.
Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia
.
BMC Public Health
.
2006
Oct
;
6
(
1
):
262
.
[PubMed]
1471-2458
22.
Umans-Eckenhausen
MA
,
Sijbrands
EJ
,
Kastelein
JJ
,
Defesche
JC
.
Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population
.
Circulation
.
2002
Dec
;
106
(
24
):
3031
6
.
[PubMed]
0009-7322
23.
Homsma
SJ
,
Huijgen
R
,
Middeldorp
S
,
Sijbrands
EJ
,
Kastelein
JJ
.
Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance
.
Eur J Hum Genet
.
2008
Jan
;
16
(
1
):
14
7
.
[PubMed]
1018-4813
24.
Sijbrands
EJ
,
Westendorp
RG
,
Defesche
JC
,
de Meier
PH
,
Smelt
AH
,
Kastelein
JJ
.
Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study
.
BMJ
.
2001
Apr
;
322
(
7293
):
1019
23
.
[PubMed]
0959-8138
25.
Versmissen
J
,
Oosterveer
DM
,
Yazdanpanah
M
,
Defesche
JC
,
Basart
DC
,
Liem
AH
, et al
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
.
BMJ
.
2008
Nov
;
337
nov11 1
:
a2423
.
[PubMed]
0959-8138
26.
Louter
L
,
Defesche
J
,
Roeters van Lennep
J
.
Cascade screening for familial hypercholesterolemia: practical consequences
.
Atheroscler Suppl
.
2017
Nov
;
30
:
77
85
.
[PubMed]
1567-5688
27.
Hampel
H
,
Frankel
WL
,
Martin
E
,
Arnold
M
,
Khanduja
K
,
Kuebler
P
, et al
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
.
N Engl J Med
.
2005
May
;
352
(
18
):
1851
60
.
[PubMed]
0028-4793
28.
Hampel
H
,
Frankel
W
,
Panescu
J
,
Lockman
J
,
Sotamaa
K
,
Fix
D
, et al
Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients
.
Cancer Res
.
2006
Aug
;
66
(
15
):
7810
7
.
[PubMed]
0008-5472
29.
Hampel
H
,
Frankel
WL
,
Martin
E
,
Arnold
M
,
Khanduja
K
,
Kuebler
P
, et al
Feasibility of screening for Lynch syndrome among patients with colorectal cancer
.
J Clin Oncol
.
2008
Dec
;
26
(
35
):
5783
8
.
[PubMed]
0732-183X
30.
The Ohio Colorectal Cancer Prevention Initiative (OCCPI)
. (https://cancerosuedu/research-and-education/pelotonia-funded-research/statewide-colon-cancer-initiative). Accessed 05.09.
2018
.
31.
Ranola
JM
,
Pearlman
R
,
Hampel
H
,
Shirts
BH
.
Modified capture-recapture estimates of the number of families with Lynch syndrome in Central Ohio
.
Fam Cancer
.
2018
.
[PubMed]
1389-9600
32.
Pearlman
R
,
Frankel
WL
,
Swanson
B
,
Zhao
W
,
Yilmaz
A
,
Miller
K
, et al;
Ohio Colorectal Cancer Prevention Initiative Study Group
.
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
.
JAMA Oncol
.
2017
Apr
;
3
(
4
):
464
71
.
[PubMed]
2374-2437
33.
Defesche
JC
.
Defining the challenges of FH screening for familial hypercholesterolemia
.
J Clin Lipidol
.
2010
Sep-Oct
;
4
(
5
):
338
41
.
[PubMed]
1933-2874
34.
Menko
FH
,
Ter Stege
JA
,
van der Kolk
LE
,
Jeanson
KN
,
Schats
W
,
Moha
DA
, et al
The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice
.
Fam Cancer
.
2018
.
[PubMed]
1389-9600
35.
Bradbury
AR
,
Patrick-Miller
L
,
Pawlowski
K
,
Ibe
CN
,
Cummings
SA
,
Olopade
OI
, et al
Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring
.
Am J Med Genet C Semin Med Genet
.
2008
Feb
;
148C
(
1
):
70
7
.
[PubMed]
1552-4868
36.
Breheny
N
,
Geelhoed
E
,
Goldblatt
J
,
Ee
H
,
O’Leary
P
.
Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma
.
Community Genet
.
2006
;
9
(
2
):
98
106
.
[PubMed]
1422-2795
37.
Burns
C
,
McGaughran
J
,
Davis
A
,
Semsarian
C
,
Ingles
J
.
Factors influencing uptake of familial long QT syndrome genetic testing
.
Am J Med Genet A
.
2016
Feb
;
170A
(
2
):
418
25
.
[PubMed]
1552-4825
38.
Shiovitz
S
,
Korde
LA
.
Genetics of breast cancer: a topic in evolution
.
Ann Oncol
.
2015
Jul
;
26
(
7
):
1291
9
.
[PubMed]
0923-7534
39.
Kuchenbaecker
KB
,
McGuffog
L
,
Barrowdale
D
,
Lee
A
,
Soucy
P
,
Dennis
J
, et al
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
.
J Natl Cancer Inst
.
2017
Jul
;
109
(
7
):
109
.
[PubMed]
0027-8874
40.
Richards
S
,
Aziz
N
,
Bale
S
,
Bick
D
,
Das
S
,
Gastier-Foster
J
, et al;
ACMG Laboratory Quality Assurance Committee
.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
.
Genet Med
.
2015
May
;
17
(
5
):
405
24
.
[PubMed]
1098-3600
41.
Boland
PM
,
Yurgelun
MB
,
Boland
CR
.
Recent progress in Lynch syndrome and other familial colorectal cancer syndromes
.
CA Cancer J Clin
.
2018
May
;
68
(
3
):
217
31
.
[PubMed]
0007-9235
42.
Di Marco
M
,
DAndrea
E
,
Panic
N
,
Baccolini
V
,
Migliara
G
,
Marzuillo
C
, et al
Which Lynch syndrome screening programs could be implemented in the “real world”? A systematic review of economic evaluations
.
Genet Med
.
2018
Oct
;
20
(
10
):
1131
44
.
[PubMed]
1098-3600
43.
Goverde
A
,
Spaander
MC
,
van Doorn
HC
,
Dubbink
HJ
,
van den Ouweland
AM
,
Tops
CM
, et al;
LIMO study group
.
Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age
.
Gynecol Oncol
.
2016
Dec
;
143
(
3
):
453
9
.
[PubMed]
0090-8258
44.
NICER
.
National Institute for Cancer Epidemiology and Registration
. http://www.nicer.org
46.
Swiss Personalized Health Network
. https://www.sphn.ch/en.html
47.
Culver
J
,
Lowstuter
K
,
Bowling
L
.
Assessing breast cancer risk and BRCA1/2 carrier probability
.
Breast Dis
.
2006-2007
;
27
(
1
):
5
20
.
[PubMed]
0888-6008
48.
Anderson
B
,
McLosky
J
,
Wasilevich
E
,
Lyon-Callo
S
,
Duquette
D
,
Copeland
G
.
Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors
.
J Cancer Epidemiol
.
2012
;
2012
:
298745
.
[PubMed]
1687-8558
49.
Ropka
ME
,
Wenzel
J
,
Phillips
EK
,
Siadaty
M
,
Philbrick
JT
.
Uptake rates for breast cancer genetic testing: a systematic review
.
Cancer Epidemiol Biomarkers Prev
.
2006
May
;
15
(
5
):
840
55
.
[PubMed]
1055-9965
50.
Stuckey
AR
,
Onstad
MA
.
Hereditary breast cancer: an update on risk assessment and genetic testing in 2015
.
Am J Obstet Gynecol
.
2015
Aug
;
213
(
2
):
161
5
.
[PubMed]
0002-9378
51.
Sharaf
RN
,
Myer
P
,
Stave
CD
,
Diamond
LC
,
Ladabaum
U
.
Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review
.
Clin Gastroenterol Hepatol
.
2013
Sep
;
11
(
9
):
1093
100
.
[PubMed]
1542-3565
52.
Caiata-Zufferey
M
,
Pagani
O
,
Cina
V
,
Membrez
V
,
Taborelli
M
,
Unger
S
, et al
Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations
.
Genet Med
.
2015
Sep
;
17
(
9
):
726
32
.
[PubMed]
1098-3600
53.
Biesecker
BB
,
Erby
L
.
Adaptation to living with a genetic condition or risk: a mini-review
.
Clin Genet
.
2008
Nov
;
74
(
5
):
401
7
.
[PubMed]
0009-9163
54.
van Oostrom
I
,
Meijers-Heijboer
H
,
Lodder
LN
,
Duivenvoorden
HJ
,
van Gool
AR
,
Seynaeve
C
, et al
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study
.
J Clin Oncol
.
2003
Oct
;
21
(
20
):
3867
74
.
[PubMed]
0732-183X
55.
Hagedoorn
M
,
Sanderman
R
,
Bolks
HN
,
Tuinstra
J
,
Coyne
JC
.
Distress in couples coping with cancer: a meta-analysis and critical review of role and gender effects
.
Psychol Bull
.
2008
Jan
;
134
(
1
):
1
30
.
[PubMed]
0033-2909
56.
Hodges
LJ
,
Humphris
GM
,
Macfarlane
G
.
A meta-analytic investigation of the relationship between the psychological distress of cancer patients and their carers
.
Soc Sci Med
.
2005
Jan
;
60
(
1
):
1
12
.
[PubMed]
0277-9536
57.
Kim
Y
,
Carver
CS
,
Spillers
RL
,
Love-Ghaffari
M
,
Kaw
CK
.
Dyadic effects of fear of recurrence on the quality of life of cancer survivors and their caregivers
.
Qual Life Res
.
2012
Apr
;
21
(
3
):
517
25
.
[PubMed]
0962-9343
58.
Northouse
LL
,
Katapodi
MC
,
Schafenacker
AM
,
Weiss
D
.
The impact of caregiving on the psychological well-being of family caregivers and cancer patients
.
Semin Oncol Nurs
.
2012
Nov
;
28
(
4
):
236
45
.
[PubMed]
0749-2081
59.
Northouse
LL
,
Katapodi
MC
,
Song
L
,
Zhang
L
,
Mood
DW
.
Interventions with family caregivers of cancer patients: meta-analysis of randomized trials
.
CA Cancer J Clin
.
2010
Sep-Oct
;
60
(
5
):
317
39
.
[PubMed]
0007-9235
60.
Katapodi
MC
,
Jung
M
,
Schafenacker
AM
,
Milliron
KJ
,
Mendelsohn-Victor
KE
,
Merajver
SD
, et al
Development of a Web-based Family Intervention for BRCA Carriers and Their Biological Relatives: Acceptability, Feasibility, and Usability Study
.
JMIR Cancer
.
2018
Apr
;
4
(
1
):
e7
.
[PubMed]
2369-1999
61.
Drummond
MF
,
Sculpher
M
,
Claxton
K
.
Methods for the Economic Evaluation of Health Care Programmes
. 4th ed.
Oxford, United Kingdom
:
Oxford University Press
;
2015
.
62.
Wonderling
D
,
Umans-Eckenhausen
MA
,
Marks
D
,
Defesche
JC
,
Kastelein
JJ
,
Thorogood
M
.
Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands
.
Semin Vasc Med
.
2004
Feb
;
4
(
1
):
97
104
.
[PubMed]
1528-9648
63.
Ademi
Z
,
Watts
GF
,
Juniper
A
,
Liew
D
.
A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia
.
Int J Cardiol
.
2013
Sep
;
167
(
6
):
2391
6
.
[PubMed]
0167-5273
64.
Ademi
Z
,
Watts
GF
,
Pang
J
,
Sijbrands
EJ
,
van Bockxmeer
FM
,
O’Leary
P
, et al
Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia
.
J Clin Lipidol
.
2014
Jul-Aug
;
8
(
4
):
390
400
.
[PubMed]
1933-2874
65.
Grosse
SD
,
Palomaki
GE
,
Mvundura
M
,
Hampel
H
.
The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates
.
Genet Med
.
2015
Jun
;
17
(
6
):
510
1
.
[PubMed]
1098-3600
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.